Literature DB >> 26900267

Dopamine and Furosemide for the Treatment of Hepatorenal Syndrome: A Reappraisal or Just Smoke and Mirrors?

Salvatore Piano1, Paolo Angeli1.   

Abstract

Entities:  

Keywords:  HRS, hepatorenal syndrome; KDIGO, Kidney Disease Improving Global Outcomes; OLT, orthotopic liver transplantation; sCr, serum creatinine

Year:  2015        PMID： 26900267      PMCID： PMC4723700          DOI： 10.1016/j.jceh.2015.12.003

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN： 0973-6883


× No keyword cloud information.
  19 in total

Review 1.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

Authors: 
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

2.  Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis.

Authors:  Yoshiyuki Narahara; Hidenori Kanazawa; Yasuhiko Taki; Yuu Kimura; Masanori Atsukawa; Tamaki Katakura; Hideko Kidokoro; Hirotomo Harimoto; Takeshi Fukuda; Yoko Matsushita; Katsuhisa Nakatsuka; Choitsu Sakamoto
Journal:  J Gastroenterol Hepatol       Date:  2009-08-03       Impact factor: 4.029

3.  Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.

Authors:  P Angeli; R Volpin; G Gerunda; R Craighero; P Roner; R Merenda; P Amodio; A Sticca; L Caregaro; A Maffei-Faccioli; A Gatta
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

4.  Circulatory function and hepatorenal syndrome in cirrhosis.

Authors:  Luis Ruiz-del-Arbol; Alberto Monescillo; Carlos Arocena; Paz Valer; Pere Ginès; Víctor Moreira; José María Milicua; Wladimiro Jiménez; Vicente Arroyo
Journal:  Hepatology       Date:  2005-08       Impact factor: 17.425

5.  Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis.

Authors:  Luis Ruiz-del-Arbol; Jesús Urman; Javier Fernández; Mónica González; Miguel Navasa; Alberto Monescillo; Agustín Albillos; Wladimiro Jiménez; Vicente Arroyo
Journal:  Hepatology       Date:  2003-11       Impact factor: 17.425

6.  Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.

Authors:  Marta Martín-Llahí; Marie-Noëlle Pépin; Mónica Guevara; Fernando Díaz; Aldo Torre; Alberto Monescillo; Germán Soriano; Carlos Terra; Emilio Fábrega; Vicente Arroyo; Juan Rodés; Pere Ginès
Journal:  Gastroenterology       Date:  2008-02-14       Impact factor: 22.682

7.  A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.

Authors:  Arun J Sanyal; Thomas Boyer; Guadalupe Garcia-Tsao; Frederick Regenstein; Lorenzo Rossaro; Beate Appenrodt; Andres Blei; Veit Gülberg; Samuel Sigal; Peter Teuber
Journal:  Gastroenterology       Date:  2008-02-13       Impact factor: 22.682

8.  The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study.

Authors:  Jean-Marie Trawalé; Valérie Paradis; Pierre-Emmanuel Rautou; Claire Francoz; Sylvie Escolano; Marion Sallée; François Durand; Dominique Valla; Didier Lebrec; Richard Moreau
Journal:  Liver Int       Date:  2009-12-18       Impact factor: 5.828

9.  An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.

Authors:  Praveen Sharma; Ashish Kumar; Brajesh C Shrama; Shiv K Sarin
Journal:  Am J Gastroenterol       Date:  2008-06-28       Impact factor: 10.864

10.  Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome--experience in 300 patients.

Authors:  T A Gonwa; C A Morris; R M Goldstein; B S Husberg; G B Klintmalm
Journal:  Transplantation       Date:  1991-02       Impact factor: 4.939
View more
  2 in total

1.  Hepatorenal syndrome: Update on diagnosis and therapy.

Authors:  Juan G Acevedo; Matthew E Cramp
Journal:  World J Hepatol       Date:  2017-02-28

2.  The Application of Dopamine Combined with Intravenous Furosemide Infusion Therapy Has an Apparent Clinical Effect in Treating Patients with Heart Failure.

Authors:  Jinzheng Shi; Rui Wang; Shaoqiang Qin; Zhanshuai Zhang; Huixian Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-18       Impact factor: 2.650
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.